Phase I Open-label Study of Low-dose Ketamine Infusion Treatment in Levodopa-Induced Dyskinesia in Parkinson’s Disease

This single-group, open-label Phase I trial evaluates low-dose intravenous ketamine infusions for treatment of levodopa-induced dyskinesia (LID) in people with Parkinson's disease, measuring acute and post-infusion effects up to weeks 2–6.

Primary outcomes include change in dyskinesia diaries and UDysRS scores; secondary measures assess duration of off/on states, pain, quality of life, and other PD symptoms per UPDRS.